Moderna (MRNA) Non-Current Deffered Revenue (2017 - 2026)

Moderna (MRNA) has 10 years of Non-Current Deffered Revenue data on file, last reported at $154.0 million in Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue rose 165.52% year-over-year to $154.0 million in Q1 2026; TTM through Mar 2026 was $154.0 million, a 165.52% increase from a year earlier, with the FY2025 full-year figure at $153.0 million, up 163.79% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $154.0 million, up from $153.0 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for MRNA reached as high as $692.0 million in Q2 2023 and fell as low as $58.0 million in Q1 2024.
• Historically, Non-Current Deffered Revenue has averaged $248.5 million across 5 years, with a median of $154.0 million in 2026.
• Across the five-year window, Non-Current Deffered Revenue sank 91.38% in 2024 and surged 165.52% in 2026, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $673.0 million in 2022, then slumped by 87.67% to $83.0 million in 2023, then tumbled by 30.12% to $58.0 million in 2024, then soared by 163.79% to $153.0 million in 2025, then climbed by 0.65% to $154.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $154.0 million in Q1 2026, $153.0 million in Q4 2025, and $157.0 million in Q3 2025.